BLINCYTO® is an immunotherapy that helps fight acute lymphoblastic leukemia (ALL). It is different from chemotherapy. BLINCYTO® works with your immune system to find and destroy cancer cells.1,2
BLINCYTO® was studied in people with ALL who had minimal residual disease, or MRD. This means that there were remaining cancer cells in their bone marrow. The goal was to become MRD-negative so there were no detectable traces of cancer left. Let’s see how well it worked.1,3
In a study of 86 adults with B-cell precursor ALL who tested MRD(+) after chemotherapy and were treated with BLINCYTO®1
8 out of 10 (81%) had no detectable cancer after 4 weeks.1,†,‡
More than half were able to go on to transplant1,§
It is important to be tested for MRD to confirm whether you still have detectable cancer. Ask your doctor if testing is a possibility for you.
*As measured by a test that can detect 1 cancer cell out of 10,000 cells in the bone marrow.1 (More sensitive testing methods may be able to detect lower levels of cancer cells.)3
†Adults studied had at least 3 rounds of chemotherapy prior to treatment with BLINCYTO®. They were in complete remission either for the first or second time.
Remission is a response to treatment where signs of cancer have disappeared, but this does not always mean the cancer is cured.1,2
‡One cycle of treatment with BLINCYTO® consists of four weeks of treatment followed by two weeks without treatment.1
§59 out of 86 patients treated with BLINCYTO® in the study proceeded to a stem cell transplant.1
BLINCYTO® may cause serious side effects that can be severe or life-threatening. These include cytokine release syndrome (CRS), infusion reactions, and neurologic problems.
Tell your health care provider right away if you develop an infection or fever.
Tell your health care provider if you have any side effects that bother you or do not go away.
These are not all the possible side effects of BLINCYTO®.
What is the most important information I should know about BLINCYTO®?
Who should not receive BLINCYTO®?
What should I avoid while receiving BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy.
The approval of BLINCYTO® in these patients is based on a study that measured response rate and duration of response. There are ongoing studies to confirm clinical benefit.
References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. National Cancer Institute. NCI dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed October 8, 2019. 3. Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012;39:47-57. 4. BLINCYTO® (blinatumomab) medication guide, Amgen.